^
Association details:
| Biomarker: | EGFR expression |
|---|---|
| Cancer: | Pancreatic Adenocarcinoma |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1)
Published date:
06/19/2020
Excerpt:
...assessed the efficacy and tolerance of gemcitabine, trastuzumab plus erlotinib as first‐line treatment of metastatic pancreatic cancer. Expression of EGFR and HER2 was correlated with PFS and OS in multivariate analysis; HER2 expression was correlated with the tumor response.
DOI:
https://doi.org/10.1002/ijc.33225
